.gif)
BioCorRx Inc.
80
Recent news coverage does not provide direct information about BioCorRx Inc.'s business activities or financial performance.
- No recent news items directly related to BioCorRx Inc.'s business or financial developments were identified in the available sources.[N1][N2][N3][N4][N5][N6][N7][N8]
BioCorRx Inc. is a publicly traded company with limited publicly disclosed information regarding its business model, sector, or industry classification. The latest SEC filings provide some financial data but do not include detailed descriptions of products, services, or customers. The company is categorized as a smaller reporting company and thus is not required to disclose extensive risk factors.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Not applicable due to limited disclosed information on business operations, growth drivers, or strategic initiatives.
The company reported a net loss and very low liquidity ratios as of June 30, 2026, with current liabilities significantly exceeding current assets. The absence of detailed business and risk disclosures increases uncertainty about financial stability and operational risks.
There is insufficient public information to assess BioCorRx Inc.'s competitive advantages or moat. The lack of detailed business and industry data limits visibility into its market position or barriers to entry.
• Liquidity Risk: As of June 30, 2026, BioCorRx had a current ratio of 0.07 and a cash ratio of 0.01, indicating potential challenges in meeting short-term obligations given current liabilities far exceed current assets.
• Limited Disclosure: The company is a smaller reporting company and is not required to provide detailed risk factors or business descriptions, which limits transparency and increases uncertainty for stakeholders.
Business trends: Limited public information restricts visibility into BioCorRx's business trends and market positioning.
Execution milestones: No disclosed execution milestones or strategic initiatives are available in recent filings or news.
Key risks: Low liquidity and limited disclosure increase uncertainty about financial stability and operational risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- BioCorRx Inc. is a publicly traded company with ticker BICX.
- As of June 30, 2026, the company reported revenue of $87,970 USD for the quarter ending that date.
- The net income for the same period was a loss of $964,774 USD.
- Basic earnings per share was reported as $1.72 USD as of June 30, 2023, while diluted EPS was -$0.03 USD as of June 30, 2026.
- Cash and cash equivalents were $111,461 USD as of June 30, 2026.
- Current assets totaled $623,377 USD as of June 30, 2026.
- Current liabilities were $8,854,703 USD as of June 30, 2026.
- The current ratio was 0.07 and the cash ratio was 0.01 as of June 30, 2026, indicating low liquidity.
- The company is classified as a smaller reporting company and is not required to provide detailed risk factors under Regulation S-K.
- No detailed business description, sector, or industry classification is disclosed in the available filings.
- Recent news items available are general market or unrelated to BioCorRx's business operations or developments.
Generated 2026-08-16
- S1 | 2026-03-31 | 10-K
- S2 | 2026-08-14 | 10-Q
- N1 | 2026-08-16 | www.nasdaq.com | ANZ Group Q3 Cash Profit Rises | https://www.nasdaq.com/articles/anz-group-q3-cash-profit-rises
- N2 | 2026-08-16 | www.nasdaq.com | These 5 AI Stocks Have Returned 300%-Plus Over the Past 3 Years -- and 1 Still Looks Dirt Cheap | https://www.nasdaq.com/articles/these-5-ai-stocks-have-returned-300-plus-over-past-3-years-and-1-still-looks-dirt-cheap
- N3 | 2026-08-16 | www.nasdaq.com | President Donald Trump Claims Costs Are "All Coming Down Now," but the Evolution of Trumpflation Appears to Be Having the Opposite Effect | https://www.nasdaq.com/articles/president-donald-trump-claims-costs-are-all-coming-down-now-evolution-trumpflation-appears
- N4 | 2026-08-16 | www.nasdaq.com | What Other Restaurant Chains Should Learn From The Cheesecake Factory's Success | https://www.nasdaq.com/articles/what-other-restaurant-chains-should-learn-cheesecake-factorys-success
- N5 | 2026-08-16 | www.nasdaq.com | Social Security COLA Watch 2027: Here's the Latest on What to Expect | https://www.nasdaq.com/articles/social-security-cola-watch-2027-heres-latest-what-expect
- N6 | 2026-08-16 | www.nasdaq.com | IonQ Paid $1.8 Billion for a Chip Foundry. Here's What Investors Should Know. | https://www.nasdaq.com/articles/ionq-paid-18-billion-chip-foundry-heres-what-investors-should-know
- N7 | 2026-08-16 | www.nasdaq.com | Cintas Hit a Record 51% Margin. Here's Why Five Insider Filings Don't Change the Story | https://www.nasdaq.com/articles/cintas-hit-record-51-margin-heres-why-five-insider-filings-dont-change-story
- N8 | 2026-08-16 | www.nasdaq.com | Stocks Close Lower on Worries About US Economy | https://www.nasdaq.com/articles/stocks-close-lower-worries-about-us-economy
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.
Generated by Valye SEC Pipeline Engine